Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia
Hussain, M.; Shad, M.N.; Akhtar, L.
JPMA. Journal of the Pakistan Medical Association 67(12): 1884-1888
2017
ISSN/ISBN: 0030-9982 PMID: 29256535 Document Number: 694028
To determine the effect of pioglitazone on cardiometabolic risk factors in non-diabetic patients with dyslipidaemia. This prospective, randomised clinical trial was conducted at Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, Pakistan, from August to October 2016, and comprised non-diabetic patients with dyslipidaemia. They were randomly divided into three groups. First and second groups were given a daily dose of tab pioglitazone 30mg and gemfibrozil 600mg, respectively, while the third group served as the healthy control. Body weight, body mass index and serum lipid profile were analysed pre- and post-treatment. SPSS 16 was used for data analysis. Of the 135 participants, there were 45(33.3%) in each group. After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10.5 to 76±13.5kg) and body mass index (27.7±4.4 to 25.5±6.4kg/m2) (p<0.01) compared to the gemfibrozil group. The pioglitazone group showed a significant improvement in serum lipid profile after 12 weeks (p<0.05) while the gemfibrozil group showed a highly significant improvement in serum lipid profile (p<0.01). Pioglitazone independently improved cardiometabolic risk factors, even in non-diabetics.